Effect of AMP-activated protein kinase subunit alpha 2 (PRKAA2) genetic polymorphisms on susceptibility to type 2 diabetes mellitus and diabetic nephropathy in a Chinese population.
BACKGROUND
It is well known that AMP-activated protein kinase (AMPK) is a key factor affecting the development of type 2 diabetes mellitus (T2DM). The single nucleotide polymorphism (SNP) rs2746342 in the AMPK alpha 2 subunit gene (PRKAA2) has been found to be associated with susceptibility to T2DM in the Chinese Han population. The present study further investigates the association of PRKAA2 genotypes with susceptibility to T2DM and its complication, diabetic nephropathy.


METHODS
The PRKAA2 genotypes of 406 T2DM patients and 214 controls from the Chinese Han population were determined with regard to SNPs rs10789038, rs2796498 and rs2746342. The association between these SNPs and susceptibility to T2DM and diabetic nephropathy was evaluated. The clinical characteristics differed significantly between T2DM patients and controls.


RESULTS
After adjustment for age, sex and body mass index, there was an obvious relationship between T2DM and both rs10789038 (odds ratio [OR] 1.634; P = 0.015) and rs2796498 (OR 0.656; P = 0.030), but not rs2746342. There was haplotype association of PRKAA2 rs10789038-rs2796498-rs2746342 with T2DM susceptibility. In addition, rs2796498 was found to be related to the susceptibility to diabetic nephropathy.


CONCLUSIONS
Polymorphisms in rs10789038 and rs2796498 are associated with the susceptibility to T2DM, and rs2796498 may be related to diabetic nephropathy.
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.|Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.|Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.
Qingchu
Q
Li
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.|Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha, China.
Cuilin
C
Li
Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.|Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.
Haoyun
H
Li
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.|Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha, China.
Liu
L
Zeng
Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.|Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.
Zhiqiang
Z
Kang
Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.|Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.
Yu
Y
Mao
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.|Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha, China.
Xinyue
X
Tang
Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.|Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.
Panpan
P
Zheng
Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.|Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.
Li
L
He
Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.|Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China.
Fang
F
Luo
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.|Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha, China.
Zhi
Z
Li
D055372:AMP-Activated Protein Kinases / Q000235:genetics*; D044466:Asian People / Q000235:genetics*; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000453:epidemiology / Q000235:genetics*; D003928:Diabetic Nephropathies / Q000453:epidemiology / Q000209:etiology / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D015810:Linkage Disequilibrium; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide
C526181:PRKAA2 protein, human; D055372:AMP-Activated Protein Kinases
2型糖尿病; AMP-activated protein kinase subunit alpha 2 (PRKAA2); PRKAA2; diabetic nephropathy; polymorphism; type 2 diabetes mellitus; 多态性; 糖尿病肾病